BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 24035867)

  • 1. Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications.
    Kopchick JJ; List EO; Kelder B; Gosney ES; Berryman DE
    Mol Cell Endocrinol; 2014 Apr; 386(1-2):34-45. PubMed ID: 24035867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone receptor antagonists.
    Kohn DT; Kopchick JJ
    Minerva Endocrinol; 2002 Dec; 27(4):287-98. PubMed ID: 12511851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.
    Kopchick JJ; Parkinson C; Stevens EC; Trainer PJ
    Endocr Rev; 2002 Oct; 23(5):623-46. PubMed ID: 12372843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly].
    Zgliczyński W; Zdunowski P
    Endokrynol Pol; 2007; 58(5):408-16. PubMed ID: 18058736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth.
    Divisova J; Kuiatse I; Lazard Z; Weiss H; Vreeland F; Hadsell DL; Schiff R; Osborne CK; Lee AV
    Breast Cancer Res Treat; 2006 Aug; 98(3):315-27. PubMed ID: 16541323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocytosis and Degradation of Pegvisomant and a Potential New Mechanism That Inhibits the Nuclear Translocation of GHR.
    Lan H; Li W; Li R; Zheng X; Luo G
    J Clin Endocrinol Metab; 2019 Jun; 104(6):1887-1899. PubMed ID: 30602026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons learned from studies with the growth hormone receptor.
    Kopchick JJ
    Growth Horm IGF Res; 2016 Jun; 28():21-5. PubMed ID: 26216709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model.
    Evans A; Jamieson SM; Liu DX; Wilson WR; Perry JK
    Cancer Lett; 2016 Aug; 379(1):117-23. PubMed ID: 27241667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Agouti-Related Protein Levels in Acromegaly and Effects of Surgical or Pegvisomant Therapy.
    Freda PU; Reyes-Vidal C; Jin Z; Pugh M; Panigrahi SK; Bruce JN; Wardlaw SL
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5453-5461. PubMed ID: 31361303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GH Action in Prostate Cancer Cells Promotes Proliferation, Limits Apoptosis, and Regulates Cancer-related Gene Expression.
    Unterberger CJ; Maklakova VI; Lazar M; Arneson PD; Mcilwain SJ; Tsourkas PK; Hu R; Kopchick JJ; Swanson SM; Marker PC
    Endocrinology; 2022 May; 163(5):. PubMed ID: 35383352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly.
    Drake WM; Parkinson C; Besser GM; Trainer PJ
    Trends Endocrinol Metab; 2001 Nov; 12(9):408-13. PubMed ID: 11595543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and uses of pegvisomant: a growth hormone antagonist.
    Berryman DE; Palmer AJ; Gosney ES; Swaminathan S; DeSantis D; Kopchick JJ
    Endokrynol Pol; 2007; 58(4):322-9. PubMed ID: 18058724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and mechanism of action of pegvisomant.
    Kopchick JJ
    Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S21-5. PubMed ID: 12670297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegvisomant in the treatment of acromegaly.
    Parkinson C; Scarlett JA; Trainer PJ
    Adv Drug Deliv Rev; 2003 Sep; 55(10):1303-14. PubMed ID: 14499709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GH receptor antagonist: mechanism of action and clinical utility.
    Surya SK; Barkan AL
    Rev Endocr Metab Disord; 2005 Jan; 6(1):5-13. PubMed ID: 15711909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.
    Yin D; Vreeland F; Schaaf LJ; Millham R; Duncan BA; Sharma A
    Clin Cancer Res; 2007 Feb; 13(3):1000-9. PubMed ID: 17289896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use of pegvisomant for the treatment of acromegaly.
    Drake WM; Trainer PJ
    Treat Endocrinol; 2003; 2(6):369-74. PubMed ID: 15981941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.